A study presented at Retina Subspecialty Day at the American Academy of Ophthalmology meeting in Chicago showed that a Fas inhibitor demonstrated strong efficacy signals in patients with more than 8 days of macula-off rhegmatogenous retinal detachment. The study assessed the safety and efficacy of intravitreal ONL1204 in these patients, with results showing a trend toward neuroprotection in patients with longer macula-off status. Patients treated with ONL1204 experienced better improvements in visual acuity compared to those receiving a sham treatment. Further research will focus on patients at highest risk of vision loss.
Source link
Fas inhibitor shows benefit in some cases of macula-off rhegmatogenous retinal detachment
